Creative Planning boosted its stake in shares of TESARO, Inc. (NASDAQ:TSRO) by 2,328.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,358 shares of the biopharmaceutical company’s stock after buying an additional 29,108 shares during the period. Creative Planning owned 0.06% of TESARO worth $4,246,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TSRO. FMR LLC increased its stake in TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock worth $1,237,718,000 after buying an additional 32,918 shares in the last quarter. BlackRock Inc. increased its stake in TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after buying an additional 3,335,611 shares in the last quarter. Vanguard Group Inc. increased its stake in TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock worth $448,705,000 after buying an additional 103,759 shares in the last quarter. State Street Corp increased its stake in TESARO by 0.4% in the first quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock worth $152,617,000 after buying an additional 3,784 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock worth $103,954,000 after buying an additional 175,273 shares during the last quarter.

Shares of TESARO, Inc. (TSRO) opened at 127.30 on Tuesday. The company’s 50 day moving average price is $135.83 and its 200-day moving average price is $150.77. The stock’s market capitalization is $6.86 billion. TESARO, Inc. has a 52 week low of $83.26 and a 52 week high of $192.94.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.26) by $0.29. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.84 million. During the same period in the previous year, the firm earned ($2.22) earnings per share. The company’s revenue for the quarter was up 909.8% compared to the same quarter last year. Equities research analysts predict that TESARO, Inc. will post ($8.56) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/08/tesaro-inc-tsro-shares-bought-by-creative-planning-updated-updated-updated.html.

A number of research analysts have recently weighed in on the company. ValuEngine raised TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Credit Suisse Group set a $198.00 price objective on TESARO and gave the company a “buy” rating in a research report on Wednesday, July 19th. BidaskClub cut TESARO from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Janney Montgomery Scott reaffirmed a “neutral” rating on shares of TESARO in a research report on Friday, July 14th. Finally, Gabelli began coverage on TESARO in a report on Friday, July 7th. They issued a “buy” rating and a $175.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $177.54.

In related news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 34.60% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.